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Background: Alpha-1 proteinase inhibitor (API) is a plasma serpin superfamily member that inhibits neutrophil
elastase; variant API M358R inhibits thrombin and activated protein C (APC). Fusing residues 1-75 of another serpin,
heparin cofactor II (HCII), to API M358R (in HAPI M358R) was previously shown to accelerate thrombin inhibition
over API M358R by conferring thrombin exosite 1 binding properties. We hypothesized that replacing HCII 1-75
region with the 13 C-terminal residues (triskaidecapeptide) of hirudin variant 3 (HV354-66) would further enhance the
inhibitory potency of API M358R fusion proteins. We therefore expressed HV3API M358R (HV354-66 fused to API
M358R) and HV3API RCL5 (HV354-66 fused to API F352A/L353V/E354V/A355I/I356A/I460L/M358R) API M358R) as
N-terminally hexahistidine-tagged polypeptides in E. coli.
Results: HV3API M358R inhibited thrombin 3.3-fold more rapidly than API M358R; for HV3API RCL5 the rate
enhancement was 1.9-fold versus API RCL5; neither protein inhibited thrombin as rapidly as HAPI M358R. While the
thrombin/Activated Protein C rate constant ratio was 77-fold higher for HV3API RCL5 than for HV3API M358R, most
of the increased specificity derived from the API F352A/L353V/E354V/A355I/I356A/I460L API RCL 5 mutations, since
API RCL5 remained 3-fold more specific than HV3API RCL5. An HV3 54-66 peptide doubled the Thrombin Clotting
Time (TCT) and halved the binding of thrombin to immobilized HCII 1-75 at lower concentrations than free HCII
1-75. HV3API RCL5 bound active site-inhibited FPR-chloromethyl ketone-thrombin more effectively than HAPI RCL5.
Transferring the position of the fused HV3 triskaidecapeptide to the C-terminus of API M358R decreased the rate of
thrombin inhibition relative to that mediated by HV3API M358R by 11-to 14-fold.
Conclusions: Fusing the C-terminal triskaidecapeptide of HV3 to API M358R-containing serpins significantly increased
their effectiveness as thrombin inhibitors, but the enhancement was less than that seen in HCII 1-75–API M358R fusion
proteins. HCII 1-75 was a superior fusion partner, in spite of the greater affinity of the HV3 triskaidecapeptide, manifested
both in isolated and API-fused form, for thrombin exosite 1. Our results suggest that HCII 1-75 binds thrombin exosite 1
and orients the attached serpin scaffold for more efficient interaction with the active site of thrombin than the
HV3 triskaidecapeptide.
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Alpha-1-proteinase inhibitor (API) belongs to the serpin
superfamily, a class of proteins whose members typically
form inhibitory complexes with the serine proteinases
they regulate [1-4]. API is the most abundant serpin in
mammalian plasma, circulating at a concentration of 20-
50 μM [5]. API protects tissues from attack by inflam-
matory proteinases; notably, in alveolar fluid it protects
lung parenchymal cells and elastin from destruction by
neutrophil elastase [6]. This physiological role is under-
scored by the increased risk of emphysema manifested
by individuals with hereditary deficiency of API [6]. API
also inhibits other serine proteinases such as thrombin
[7], coagulation factor XIa [8], and activated protein C
(APC) [9], but at rates at least six orders of magnitude
less rapid than its inhibition of elastase; it also efficiently
inhibits trypsin, but would not be expected to come in
contact with this digestive system enzyme under physio-
logical conditions.
Serpins inhibit their cognate proteinases via a complex
mechanism initiated when the reactive centre loop
(RCL) surface structure forms an encounter complex
with the active site of a protease [2]. Attack of the prote-
ase on the reactive centre scissile bond of the RCL trig-
gers the release of stored energy [10], a rapid insertion
of the RCL into an underlying β-sheet [11], and a major
translocation of the protease [12], still attached to the
RCL as a covalently bound acyl intermediate [13], to the
opposite pole of the serpin. The rapid translocation
distorts the active site of the protease, preventing com-
pletion of the catalytic cycle [14,15], and rendering the
serpin inhibitory complex physiologically irreversible.
Crystal structures of API in intact form [16], in RCL-
cleaved form [17], in encounter complexes with trypsin
[18], and in covalent serpin-enzyme complexes with
trypsin [15] and elastase [14] have contributed to the
elucidation of this mechanism.
The naturally occurring Pittsburgh mutation, of the
scissile bond in API from M358-S359 to R358-S359, was
discovered in a patient with an ultimately fatal bleeding
tendency [19], although two other unrelated individuals
with the same mutation and clinically milder conse-
quences have since been reported [20,21]. Mutant API
M358R was found to inhibit thrombin [19,22], factor
XIa [22], and APC [23] from 5,000-to 8,000-fold more
rapidly than its wild-type counterpart. Our group [24,25]
and others [26,27] have reported that introducing add-
itional mutations into the RCL of API M358R enhanced
its specificity as a thrombin inhibitor, primarily by de-
creasing its potency as an APC inhibitor. Noting that
the 75 amino acid N-terminal acidic extension of hep-
arin cofactor II (HCII), a thrombin-specific inhibitory
serpin, had no counterpart in API [1], we fused HCII 1-
75 to API M358R, and demonstrated a > 5-fold increasein the rate of thrombin inhibition [24,28], and a superior
ability to limit thrombus size in murine arterial and ven-
ous thrombosis models, relative to API M358R [29].
The acidic extension of HCII accelerates thrombin inhib-
ition by binding to thrombin exosite 1, a cluster of charged
residues involved in binding thrombin co-factors such as
thrombomodulin and substrates such as fibrinogen and co-
agulation factor V [30]. This deduction is supported by: a
partially resolved X-ray crystal structure of the HCII-S195A
thrombin structure [31]; reduced rates of inhibition of HCII
and HCII fusion proteins on exosite-1-disrupted forms of
thrombin [32-35]; and direct binding studies of either HCII
1-75 or its smaller derivatives [36,37]. The leech anticoagu-
lant protein hirudin is the most potent known polypeptide
inhibitor of thrombin [38], and owes some of its high affin-
ity for thrombin to the binding of its 11-13 C-terminal
residues, depending on the isoform [39], to thrombin exo-
site 1. We [36] and others [37] have demonstrated that hi-
rudin C-terminal peptides bind more tightly to thrombin
than HCII 1-75 or its derivatives. Accordingly, in the
current study we tested the primary hypothesis that fusion
of the C-terminal 13 amino acids of hirudin variant 3
(HV3), the most potent hirudin isoform [39], to API
M358R, would increase the rate of thrombin inhibition of
API M358R by conferring on this mutant serpin the ability
to bind thrombin exosite 1. We also addressed our second-
ary hypothesis, that an HV3 fusion to API M358R would




The HV3 peptides, HV354-66, H6HV354-66, and H6HV354-66
G6 (whose amino acid sequences are depicted in Figure 1,
panel A) were produced by solid phase synthesis using
9-fluorenylmethyloxycarbonyl (Fmoc) chemistry, and pur-
chased from the Advanced Protein Technology Center, The
Hospital for Sick Children, (Toronto, ON).
Construction of pBAD-H6HV3API M358R and pBAD-
H6HV3API RCL5
All oligonucleotides used in this work were synthesized
by the Institute for Molecular Biology and Biotechnology
(MOBIX) at McMaster University (Hamilton, ON); the
same facility provided DNA sequencing services used to
confirm the bona fide nature of all candidate constructs.
Previously described plasmids pBAD-H6HAPI M358R
[28] and pBAD-H6HAPI RCL5 [24] were used as tem-
plates in PCR mediated by Phusion polymerase (New
England Biolabs, Pickering, ON) in reactions primed
by oligonucleotides 5′-CACCATGGGG TCTCATCATC
ATCATCATCA TGGAGACTTT GAGCCTATCC CTG
AGGATGC CTATGATGAG GGTGGAGGTG GAG GT
GGAG AGGATCCCCA G-3′and 5′-CCGGAATTCT
Figure 1 Schematic and electrophoretic representation of proteins and peptides employed. Polypeptides comprising portions of API
M358R (hatched bar, with residue numbers above) with or without N-terminal extensions (white) derived from HCII (symbols inset, and residue
number below) or HV3 (symbol inset, and residue numbers below) are represented schematically in Panel A. Each protein contains an N-terminal
MGSH6 tag (at left of each schematic representation, thin grey bar). Fusion proteins contain a spacer peptide (thin black bar) following the
N-terminal extension of either 6 or 8 residues identified above the bar. Reactive centre loop (RCL) sequences are either API M358R (open box,
with exploded sequence below) or M358R with additional F352A/L353V/E354V/A355I/I356A/I460L substitutions (RCL5, with open box inset “5”,
and exploded sequence below). Recombinant proteins are identified to the right of each bar diagram. Panel B shows a reduced 12% SDS
polyacrylamide gel stained with Coomassie Brilliant Blue. Ara-and Ara + lanes show total bacterial lysates from cultures expressing HV3API M358R
grown in the presence or absence of 0.002% (w/vol) arabinose. Aliquots of bacterial lysates purified by nickel chelate chromatography
(FT, flow-through; Ni, imidazole-eluted peak fractions; DEAE, final preparation following ion exchange on DEAE-Sepharose) are shown. Panel C
shows two replicas of a reduced SDS gel loaded with 100 ng of each of the purified proteins identified above the lanes (GST; glutathione
sulfotransferase, negative control) immunoblotted with either anti-API (upper panel) or anti-hexahistidine (anti-H6, lower panel). Panel D shows a
reduced 12% SDS gel stained with Coomassie Brilliant Blue, containing 250 ng of each of the purified proteins identified above the lanes
electrophoresed. The positions of molecular mass markers are labelled, in kDa, to the left of Panels B-D.
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buffer and cycling conditions recommended by the en-
zyme manufacturer. The amplification products were re-
stricted with Nco1 and EcoRI and the resulting 1271 bp
fragments ligated between the corresponding sites in
the plasmid pBADmychisB (Invitrogen, La Jolla, CA),
producing novel plasmids pBAD-H6HV3API M358R
and pBAD-H6HV3API RCL5, respectively. The open
reading frame encoded by pBAD-H6HV3API M358R is
depicted in Figure 1, Panel A, and comprised 421 co-
dons specifying nonapeptide MGSH6, HV3 residues 54-
66, spacer residues G6, and API M358R, in that order,from predicted N-terminus to C-terminus. The polypep-
tide encoded by pBAD-H6HV3API M358R was identical,
except for the substitution of AVVIA for residues 352-356
inclusive (FLEAI) and of I360L, as previously described
for API RCL5 [24].
Construction of pBAD-H6API M358R-HV3 and pBAD-H6API
M358R-G6HV3
In order to position HV354-66 on the C-terminus of API
M358R and API RCL5, an analogous PCR-mediated mu-
tagenesis protocol was employed to that described
above. Two constructs were made: one encoding API
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M358R-HV3); and the second with a G6 spacer inter-
posed between the API and HV3 components (API
M358R-G6HV3). The entire open reading frame was
PCR-amplified using sense oligonucleotide 5′-ATGCCA-
TAGC ATTTTTATCC-3′ and antisense oligonucleo-
tides 5′-TTCGAATTCT TACTCATCAT AGGCATCC
TC AGGGATAGGC TCAAAGTCTC CTTTTTGGGT
GGGATTCACC AC and 5′-TTCGAATTCT TACTC
ATCAT AGGCATCCTC AGGGATAGGC TCAAAGTC
TC CTCCACCTCC ACCTCCACCT TTTTGGGTGG
GATTCACCAC-3′, respectively. Resulting plasmid pBAD-
H6API M358R-HV3 encoded the 407 amino acid poly-
peptide API M358R-HV3, while resulting plasmid
pBAD-H6API M358R-G6HV3 encoded the 413 amino
acid polypeptide API-M358R-G6HV3.Expression and purification of API M358R and related
recombinant proteins
His-tagged recombinant proteins were purified from
bacterial cell lysates prepared from arabinose-induced E.
coli TOP10 cells transformed to ampicillin resistance
by either previously described plasmid pBAD-H6HAPI
M358R or pBAD-H6HAPI RCL5 or with one of the
four novel plasmids described above. The same purifi-
cation protocol was employed, utilizing Ni-NTA agarose
(Qiagen) and DEAE-Sepharose (GE Healthcare, Baie
d’Urfe, QC) chromatography of lysates from sonically
disrupted bacteria as previously described [28], except
that the elution fractions from nickel-chelate chroma-
tography were dialyzed overnight in 20 mM sodium
phosphate pH 6.8 prior to ion exchange chromato-
graphy on DEAE Sepharose (GE Health Care, Baie d’Urfe,
QC), and a linear gradient of 0 to 300 nM NaCl in
20 mM sodium phosphate pH 6.8 was used to develop
the DEAE Sepharose column. Fractions containing the
protein of interest as determined by SDS-PAGE were
pooled and concentrated using an Amicon Ultra-15 Cen-
trifugal Filter Unit (EMD Millipore, Billerica, MA) and
stored at −80°C. The concentrations of all recombinant
serpin proteins were determined using spectrophotom-
etry at OD280 nm, and calculated molar extinction coef-
ficients based on their primary sequences, as described
previously [40].Expression and purification of HCII 1-75
A small recombinant protein, 84 amino acids in size,
comprising residues 1-75 of HCII with an N-terminal
nonapeptide tag MSGH6 (designated HCII 1-75), was
expressed in a pBAD-based plasmid and purified from
sonicated cell lysates by nickel-chelate affinity chroma-
tography as described [36].Thrombin clot time analysis
Thrombin clotting times were determined using an STA
4 coagulation analyzer (Diagnostica Stago, Asnieres sur
Seine, France) and the Thrombin 10 reagent (Diagnos-
tica Stago). Human citrated plasma was combined in a
1:3:5 volume ratio of plasma: veronal buffer: Thrombin
10 calcified thrombin reagent, and the time to clot was
determined. The veronal buffer (sodium acetate trihy-
drate 7.14 mM/ sodium diethyl barbiturate 7.4 mM/
NaCl 0.131 M pH7.4) was employed with or without
supplementation with purified recombinant serpins or
synthetic peptides, as described [36].
Competition of thrombin binding to immobilized
HCII 1-75
A previously described assay was employed in order to
characterize the relative affinity of recombinant serpins
and peptides for either α-thrombin or α-thrombin
rendered inactive at its active site by incubation with
FPR-chloromethylketone [36]. Briefly, purified HCII
1-75 was immobilized on microtiter plates and purified
human α-thrombin was incubated with or without com-
petitor peptides or proteins. Thrombin binding, following
washes, was detected with a horseradish peroxidase-
conjugated sheep anti-human affinity-purified antibody
(Affinity Biologicals, Ancaster, ON), binding isotherms were
solved for one-site binding by non-linear regression, and
the concentration of competitor needed to reduce the
binding by 50% (IC50) was calculated as described [36].
Gel based serpin enzyme complex analysis
The ability of HV3API M358R and API M358R to form
SDS-stable complexes with α-thrombin was measured
by incubating 1 μM serpin with 0.1 μM α-thrombin at
ambient temperature at various time points over 3 mi-
nutes. Reactions were stopped with SDS and analysed on
10% SDS-PAGE gels as previously described [28,41].
Kinetic analysis of α1-PI variants and fusion proteins
The apparent second-order rate constant (k2) of inhib-
ition of 10 nM α-thrombin or γT-thrombin by recombin-
ant serpins was determined under pseudo-first order
conditions involving a 10-to 65-fold molar excess of
serpin over protease in the first stage of a two-step
discontinuous assay, as previously described [28,42]. In
the second stage, reactions were diluted into 100 μM
chromogenic substrate S2238 (DiaPharma,West Chester
OH) and the change in absorbance at 405 nm was
followed for 5 minutes in an ELx808 plate reader
(BioTek Instruments, Winooski, VT). The same ap-
proach was used to measure the rate of inhibition of 10
nM APC by recombinant serpins, except that a 1000-
fold excess of serpin over protease was employed, and
400 μM chromogenic substrate S2366 (DiaPharma) was
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tries of α-thrombin inhibition were determined by incu-
bating recombinant serpins (0-800 nM) with 200 nM
thrombin for two hours at room temperature. This reac-
tion was diluted into 150 μM chromogenic substrate
S2238 and residual thrombin activity was measured as
described above. The number of serpin molecules re-
quired to inhibit one molecule of thrombin was calcu-
lated by plotting the residual thrombin activity versus
the ratio of serpin to thrombin and extrapolating to
complete inhibition (zero thrombin activity) by linear
regression [25,28].
Statistical analysis
Data analysis was performed using computer software
(InStat, Version 3.06, GraphPad Software, San Diego,
CA, USA); graphs were also produced with using soft-
ware from the same company (GraphPad Prism, Version
4.03). Comparisons were made between parent proteins
and modified proteins (e.g. API M358R with HV3API
M358R or API RCL5 versus HV3API RCL5) unless
otherwise stated, using parametric tests (unpaired two-
tailed t tests) if they passed conditions of normal
distribution and similarity of standard deviations, or
non-parametric tests (Mann–Whitney) if they did not
meet these conditions. A p value > 0.05 was considered
not significant in all cases.
Results
Recombinant protein design and expression
As shown in Figure 1, Panel A, as a first step in this pro-
ject, recombinant serpins were designed for expression
in E. coli. The same general strategy was employed as in
previous reports, in which the N-terminal extension of
HCII had been grafted onto either singly mutated API
M358R, or multiply mutated API RCL5 (API M358R
with six additional RCL substitutions), except that HV3
residues 54-66 was separately exchanged for HCII 1-75,
in both cases [24,29]. Induction of bacterial cultures har-
bouring expression plasmids specifying HV3API M358R
with arabinose led to the appearance of a novel 47 kDa
protein in total soluble lysate preparations, that was
enriched by nickel-chelate chromatography and purified
following an additional ion exchange step, like API
M358R and HAPI M358R (see Figure 1, Panel B). The
putative HV3API polypeptide reacted both with anti-
bodies specific to API and to hexahistidine (see Figure 1,
Panel C), and exhibited a mobility intermediate between
API M358R and HAPI M358R, consistent with its
theoretical molecule mass of 47,356 Da (see Figure 1,
Panel D). Taken together, these characteristics identi-
fied the candidate protein as HV3API M358R; similar
results were obtained for HV3API RCL5 (see Figure 1,
Panel C).Initial electrophoretic characterization of HV3API M358R
The ability of HV3API M358R to inhibit thrombin, and
form denaturation-resistant inhibitory complexes with
thrombin, was initially assessed electrophoretically under
reducing conditions. As shown in Figure 2, Panel A,
when excess purified API M358R (1.0 μM) was com-
bined with thrombin (100 nM), a 76 kDa API M358R-
IIa complex was detectable by 10 seconds elapsed time,
increasing in intensity up to 120-180 seconds, with con-
comitant disappearance of the thrombin (visualized as
the B chain under reducing conditions). Qualitatively in-
distinguishable results were obtained when HV3API
M358R was reacted with thrombin under identical
conditions (see Figure 2, Panel B), except that the
serpin-enzyme complex displayed slightly reduced mo-
bility consistent with the larger mass of HV3API M358R
(78 kDa) and the formation of a cleaved form HV3 API
M358R with slightly more rapid mobility than the intact
serpin was more pronounced compared to API M358R.
Similar results were obtained with HV3API RCL5 (data
not shown).
Kinetic characterization of HV3API M358R and
HV3API RCL5
The rate of reaction of the two API and their corre-
sponding HV3API variant proteins with α-thrombin,
γT-thrombin, and APC was quantified by determining
the second order rate constant of inhibition (k2) for each
protease. As shown in Table 1, fusing HV3 residues 54
to 66 was associated with a statistically significant,
3.3-fold increase in the mean k2 for inhibition of α-
thrombin by API M358R (p = 0.0022 by Mann–Whitney
test). Similarly, grafting the same residues from HV3
onto API RCL5 was associated with a statistically signifi-
cant, 1.9-fold increase in the mean k2 for inhibition of α-
thrombin by API RCL5 (p < 0.0001 by unpaired t test).
The mean k2 of HV3API M358R for thrombin inhib-
ition, although elevated relative to API M358R remained
2.6-fold lower than HAPI M358R, resulting in an order
of potency as thrombin inhibitors of API M358R <
HV3API M358R < HAPI M358R. Substituting γT-throm-
bin, a proteolytic derivative of intact α-thrombin possessing
only a vestigial exosite 1 [33], for the intact protease,
reduced the enhancement associated with fusion of the
HV3 residues to 1.8-fold in the case of HV3API M358R,
and 1.4-fold in the case of HV3API RCL5, although the
differences remained statistically significant, and the order
of potency remained unchanged to that observed with
α-thrombin.
With respect to the ability of the recombinant serpins
to inhibit APC, no difference was found between the
k2 determined with API M358R and that found with
HV3API M358R; in contrast the addition of HV3 resi-
dues 54-66 was associated with a 5.8-fold increase in the
Figure 2 Formation of SDS-stable complexes between fusion proteins and thrombin. Either 1.0 μM API M358R (Panel A) or 1.0 μM HV3API
M358R (Panel B) was combined with 0.2 μM thrombin (IIa) for the time in seconds shown above the lanes. Reactions were stopped with SDS
and aliquots were electrophoresed on reduced 10% SDS polyacrylamide gels, and stained with Coomassie Brilliant Blue. Thrombin-dependent
serpin-enzyme complexes with retarded mobility (either API M358R-IIa or HV3API M358R-IIa), unreacted serpins, cleaved serpins (cl API M358R or
cl HV3API M358R), or the B chain of thrombin (IIa (B)) are labelled, at right. The position of molecular mass markers is shown, in kDa, to the left of
each panel.
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unpaired t test). In terms of the relative specificity of the
recombinant serpins for α-thrombin versus APC, the
kinetic results led to a ranking of API M358R =HV3API
M358R =HAPI M358R > HV3API RCL 5 > API RCL5
(see Table 1). The stoichiometry of thrombin inhibition
(SI) was tested for API M358R, HAPI M358R, and
HV3API M358R; both fusion proteins exhibited a statis-
tically significant increase in SI, from 2.0 ± 0.3 for API
M358R to 2.4 ± 0.2 for HAPI M358R to 3.3 ± 0.1 for
HV3API M358R. The stoichiometry of APC inhibition
was not determined.
Comparison of HV3 peptides to HCII 1-75
Synthetic peptides containing HV3 residues 54-66 were
next compared to HCII 1-75, with respect to anticoagu-
lant properties and their relative abilities to bind to
α-thrombin. As shown in Figure 3, Panel A, three HV3-
related peptides were used: HV354-66, comprising only
those residues plus an MGS tripeptide on the N-terminus;
H6HV354-66, with a hexahistidine tag between MGS andTable 1 Second order rate constants (k2) of inhibition for reco





α-thrombin (×106 M-1 min-1) 22 ± 4 72 ± 15***
γT-thrombin (×10
6 M-1 min-1) 5.9 ± 0.1 11 ± 3**
APC (×106 M-1 min-1) 1.7 ± 0.1 1.9 ± 0.2
α-thrombin/ APC ratio 13 39
Kinetic analysis of protease inhibition by API fusion proteins and variants. The mean
Sutherland et al., 2007. Values that are statistically significantly different from paren
HV3API RCL5 compared to API RCL5), **, p <0.01, ***, p < 0.001 by Mann–Whitney oHV3 residues; H6HV354-66G6, with both a hexahistidine tag
and a hexaglycine spacer. As shown in Figure 3, Panel B, all
three HV3-related peptides had greater anticoagulant activ-
ity than HCII 1-75, when added into Thrombin Clotting
Time (TCT) assays at increasing concentrations in the μM
range. The order of inhibitory potency was found to be:
HV354-66 >H6HV354-66 >H6HV354-66G6 >HCII 1-75. The
concentrations of these inhibitors required to double the
TCT were, respectively (mean, in μM, ± SD): 0.45 ± 0.01;
0.93 ± 0.05; 1.6 ± 0.1; and 12 ± 4. The HV3-related peptides,
by this measure, were therefore 8-to 27-fold more potent
inhibitors of clotting than HCII 1-75.
Similar results were obtained when the HV3-related
peptides and HCII 1-75 were used as competitors of the
binding of thrombin to immobilized HCII 1-75, in a pre-
viously described binding assay [36] shown in Figure 3,
Panel C. In this assay, the order of inhibitory potency
was found to be: HV354-66 = H6HV354-66 > H6HV354-66
G6 > HCII 1-75. This order was reflected in IC50 values
derived from the inhibitory binding isotherms (mean, in
μM, ± SD) of: 0.90 ± 0.3; 0.74 ± 0.2; 1.4 ± 0.3; and 8.0 ± 1.mbinant serpins
oop Serpin with RCL5 loop
HAPI
M358R
API RCL5 HV3 API RCL5
186 ± 32*** 35 ± 8 66 ± 8***
34 ± 10** 15 ± 0.8 21 ± 3***
1.7 ± 0.2 0.0038 ± 0.0013a 0.022 ± 0.005***
109 9,211 3000
of at least 5 k2 determinations ± SD is shown (×10
6 M-1 min-1). aValue from
t protein values (HV3API M358R and HAPI M358R compared to API M358R,
r two-tailed t test. Further details are provided in the text.
Figure 3 Inhibition of thrombin clotting time and HCII 1-75-
thrombin binding assays by HV3 peptides and HCII 1-75. Panel
A depicts three synthetic peptides schematically. All contain HV3
residues 54-66 (sequence shown exploded, above first HV354-66 bar),
shown as a black bar (with “HV3” inset in white) with an MGS tripep-
tide on the N-terminus, without (HV354-66) hexahistidine or hexagly-
cine components or with only hexahistidine (H6HV354-66) or with
both hexahistidine and hexaglycine components (H6HV354-66G6).
Panel B shows the Thrombin Clotting Time (TCT) in seconds; diluted
citrated human plasma was recalcified in the presence of thrombin
and increasing concentrations of competitor peptides identified at
right. The mean ± SD of 3 to 4 determinations is shown. Panel C
shows binding of α-thrombin to immobilized HCII 1–75, expressed
as the ratio of the absorbance at 490 nm in the presence of com-
petitor (A) to that in its absence (A0); competitor peptides are identi-
fied at right. The mean ± SD of 5 to 6 determinations is shown.
Figure 4 Competition of binding of FPR-ck-thrombin to HCII
1-75 immobilized on microtiter plate wells. Binding of FPR-ck-
thrombin, expressed as the ratio of the absorbance at 490 nm,
in the presence (A) of competitor peptides (HCII 1-75 or H6HV3G6)
or competitor proteins (HAPI RCL5 or HV3API RCL5), to that in its
absence (A0), is shown. Results are the mean ± SD of five determi-
nations.
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tides were not statistically significant, but each HV3-
related peptide exhibited a significantly lower IC50 than
that of HCII 1-75 (p < 0.001 by ANOVA with Tukey-
Kramer post-tests).
Competition of binding of HCII 1-75 to active site-
inhibited thrombin
In order to extend the competitive binding experiments
to include N-terminally extended serpin fusion proteins,
focusing only on their ability to interact with thrombinvia exosite 1, and not via thrombin’s active site, we
substituted active site-inhibited FPR-ck thrombin for α-
thrombin and used peptides and fusion proteins to in-
hibit FPR-ck thrombin binding to immobilized HCII
1-75. As shown in Figure 4, HCII 1-75 was a more ef-
fective competitor in free form than when fused to API
RCL5, while H6HV354-66G6 was more effective when
fused to API RCL5 than when present in free form. This
qualitative assessment of the binding isotherm was
borne out by quantification using IC50 values, which
were determined to be (mean, in μM, ± SD): H6HV354-66
G6, 5 ±1; HV3API RCL5, 1.4 ± 0.3; HCII 1-75, 9 ± 2;
HAPI RCL5, 17 ± 2. The differences between unfused
extensions and corresponding fusion proteins in IC50
values were statistically significant (i.e. H6HV354-66G6
versus HV3API RCL5, p = 0.002 by unpaired t test, and
HCII 1-75 versus HAPI RCL5, p = 0.003 by unpaired t
test) but qualitatively reversed, in that HCII 1-75 was a
more effective competitor of FPR-ck thrombin binding
in free form while H6HV354-66G6 was a more effective
competitor when present in fused form. Overall,
HV3API RCL5 was also a better ligand for thrombin
exosite 1 than HAPI RCL5.
Gel-based and kinetic activity assays of C-terminal HV3 fu-
sions to API M358R
Two additional fusion proteins were designed, expressed,
and purified, using the same arabinose-inducible bacter-
ial expression system employed throughout this study, in
order to determine if appending the HV3 triskaidecapep-
tide to the C-terminus of API M358R, a location corre-
sponding to its natural position on the C-terminus of
HV3, would yield a more active thrombin-inhibitory
serpin. As shown in Figure 5, Panel A, API-HV3 was de-
signed to be identical to API M358R except for the C-
terminal addition of HV3 54-66; API-G6-HV3, in turn,
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G6 spacer between API Lys394 and HV3 Glu66. Purified
API-G6-HV3 co-migrated with purified HV3 API M358R,
as expected given their identical amino acid composition,
but different amino acid sequence, while purified API-HV3Figure 5 Formation of SDS-stable complexes between thrombin and
Polypeptides comprising portions of API M358R (hatched bar, with residue
from HV3 (with single “minus sign” symbols inset, and residue numbers be
an N-terminal MGSH6 tag (shown at left of each schematic representation
tain (API-HV3) a six residue spacer peptide (thin black bar) between C-term
centre loop (RCL) sequences are API M358R (open box) in both cases. Pan
massie Brilliant Blue. Proteins identified above the lanes were incubated (1.
ambient temperature for 1.0 minute. The position of the serpin-enzyme co
serpin (S), cleaved serpin (CS) and the B chain of thrombin (IIa (B)) is shown
70, 60, 50, 40, and 30 kDa, respectively. Panel C shows a plot of the second
M-1 min-1) of the purified proteins identified, in each case, below the x axis
Lines between the columns indicate statistical significance (non-parametric
0.001; n.s., not significant).migrated slightly more rapidly than the other two recom-
binant proteins, consistent with its lacking the hexaglycine
sequence present in the other two (see Figure 5, Panel B,
“-IIa” lanes). When all three proteins were separately incu-
bated in identical excess of α-thrombin, less serpin-enzymeN-terminal or C-terminal HV3 54-66–API M358R fusion proteins.
numbers above) with or without C-terminal extensions (white) derived
low) are represented schematically in Panel A. Each protein contains
as a thin grey bar). Fusion proteins contain (API-G6-HV3) or do not con-
inal extension and API M358R body identified above the bar. Reactive
el B shows a reduced 10% SDS polyacrylamide gel stained with Coo-
0 μM serpin, 0.2 μM thrombin) without (−) or with (+) thrombin (IIa) at
mplex (SEC) is highlighted with arrowheads. The position of unreacted
at right. M indicates molecular mass markers of 160, 120, 100, 90, 80,
order rate constants of thrombin inhibition (k2, in units of 10
6
. The mean ± SD for 9, 6, and 5 replicated determinations is shown.
ANOVA, Kruskal-Wallis test with Dunn’s post-tests): *, p < 0.05; ***, p <
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case of the C-terminal HV3 fusions than was observed with
HV3API M358R (see Figure 5, Panel B). Densitometry of
the stained gel supported this visual impression, and
showed that while 37% of initial HV3API M358R was con-
verted into a covalent complex with thrombin, only 15% of
API-G6-HV3 and 32% of API-HV3 reacted in the same
manner. The rates of reaction of these three proteins were
further compared by kinetic analysis (see Figure 5, Panel
C). The second order rate constant of inhibition (k2)
for the three inhibitors was found to be 60 ± 20 for
HV3API, 5.7 ± 0.3 for API-G6-HV3, and 4.5 ± 0.4 for
API-HV3 (all ×106 M-1 min-1, mean ± SD of 9, 6, and 5
determinations). These 11-and 14-fold reductions in
the rate of thrombin inhibition by the API variants
with C-terminal fusions of the HV3 C-terminal triskai-
decapeptides were statistically significant (p < 0.05 and
p <0.001 versus HV3API M358R value; see Figure 5C).
Discussion
In this study we sought to enhance the inhibitory po-
tency of API M358R, a variant form of API that in-
hibits thrombin. Our primary hypothesis was that
fusion of the C-terminal triskaidecapeptide of hirudin
to the N-terminus of API M358R would increase the
rate of reaction of the resulting novel engineered ser-
pin with thrombin. Our reasoning was based on our
previous demonstration that fusion of the N-terminal
75 amino acids of HCII increased the reactivity of API
M358R and other forms of API with thrombin; both
HCII 1-75 and the C-terminal region of hirudin are
known to interact with thrombin exosite 1. Deletion of
HCII 1-75 in HCII reduced the rate of thrombin inhib-
ition of recombinant HCII [32,34,43,44] and adding
HCII 1-75 to API M358R increased it [28]. Our secondary
hypothesis was that fusing the exosite 1-binding motif from
hirudin to API M358R or RCL5 would accelerate the rate
of thrombin inhibition by API M358R to a greater extent
than fusing HCII 1-75. Our reasoning here was based on
observations that hirudin C-terminal peptides bound
thrombin with higher affinity than that exhibited by HCII
1-75 or relative peptides [36,37].
Our results supported our first hypothesis. Fusing
HV3 residues 54-66 to either API M358R or API RCL
significantly increased the rate of thrombin inhibition of
these recombinant serpins, by approximately 3-fold. The
effect was reduced when γT-thrombin was substituted
for α-thrombin, consistent with the enhancement being
tied to the presence of a fully functional exosite 1; this
exosite is largely disrupted by trypsin-mediated proteolysis
in γT-thrombin [33]. The enhancement was thrombin-
specific, in that no change in APC inhibition rate was found
between API M358R and HV3API M358R. While it is true
that HV3AP1 RCL5 exhibited a 5-fold more rapid rate ofAPC inhibition than API RCL5, both proteins were poor
inhibitors of APC, with the reduction in APC inhibition
rate being derived primarily from the antithrombin-like
RCL found in the RCL5 proteins; a similar phenomenon
was previously noted for fusion protein HAPI M358R,
likely indicative of overall stabilization of the fusion protein,
since APC contains no known analogues of thrombin
exosite 1 [28]. As expected based on the precedent of alter-
ing HAPI M358R to HAPI RCL5, there was no further
increase in the rate of thrombin inhibition gained by
altering HV3API M358R to HV3API RCL5, but instead a
considerable increase in specificity attributable to the de-
creased ability of API M358R variants bearing this more
antithrombin-like RCL to inhibit APC [24,26].
Serpins follow a branched reaction pathway with
proteases, acting either as inhibitors or substrates. We
previously reported the ratio between substrate and in-
hibitor outcomes, the stoichiometry of inhibition, as
being similar between API M358R and HAPI M358R,
of 2.9 to 3.2. In the current study we found that API
M358R had the least tendency to act as a substrate,
with an SI of 2.0, while the acquisition of a faster rate
of inhibition of HAPI M358R (mean SI 2.4) and in par-
ticular HV3API M358R (mean SI 3.3), had been
achieved at the cost of greater substrate-like behavior.
In contrast to the general findings discussed above that
supported our primary hypothesis, our second hypothesis
was not supported by our results. We first followed
thrombin-serpin complex formation using gel-based assays.
While these experiments revealed no unusual complex in-
stability of the novel variant serpins, as has been previously
reported for some variants [42,45-47], they also showed no
discernible difference in the rate of thrombin inhibition be-
tween API M358R and the HV3-containing fusion proteins.
This finding suggested that the rate enhancement was likely
less than 5-to 10-fold, given our previously demonstrated
ability to note a rate enhancement with the relatively in-
sensitive electrophoretic assay in this range of difference
[24,29]. This prediction was borne out in the kinetic ana-
lysis. HV3API M358R exhibited a mean k2 of α-thrombin
inhibition of 7.2 × 107 M-1 min-1, one clearly inferior to rate
constants we reported for HAPI M358R of 1.4 to 2.3 ×
108 M-1 min-1 [28,29].
To explain why we had failed to capitalize on the
greater affinity of the hirudin C-terminal motif than
HCII 1-75 for thrombin exosite 1 in HV3API M358R,
we considered the possibility that our selection of the C-
terminal residues of hirudin variant 3, rather than other
variants of hirudin, was to blame. This explanation was
eliminated by our finding that synthetic peptides com-
prising HV3 54-66, with or without the hexaglycine or
hexahistidine motifs present in HV3API M358R, inhib-
ited thrombin-mediated clotting assays and competed
for the binding of thrombin to immobilized HCII 1-75
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was consistent with our previous demonstration of a
ten-fold advantage of a hirudin variant 1 55-65 peptide
over HCII 1-75 as an exosite 1 ligand, deduced using
surface plasmon resonance [36]. Substituting FPR-ck-
thrombin for α-thrombin in the immobilized HCII 1-75
binding assay next permitted comparisons of the free
and fused versions of the HV3 and HCII 1-75 exosite 1-
binding motifs to be made. HCII 1-75 bound thrombin
exosite 1 better in free form than in the context of the
HAPI RCL5 fusion protein, while HV3 54-66 in the
HV3API RCL5 context was a superior ligand not only in
comparison to either free or fused HCII 1-75 but also in
comparison to its unfused form. This advantage in bind-
ing thrombin exosite 1 was not translated into superior-
ity as a serpin; HV3API RCL5 exhibited a mean k2 for
α-thrombin inhibition of 6.6 × 107 M-1 min-1 compared
to 1.4 × 108 M-1 min-1 for HAPI RCL5.
The differences uncovered between the ability of the
fusion proteins to bind thrombin exosite 1 and theFigure 6 Schematic comparison of reactions of thrombin with natural an
(yellow) with heparin-activated HCII or HCII-API fusion protein HAPI M358R (blu
labelled exosite 1 (exo) encounters heparin-activated HCII or fusion protein HA
and a Reactive Centre Loop (RCL, blue triangle) on a serpin scaffold (blue large
with thrombin’s active site guide the serpin into productive encounter comple
serpin-enzyme complex formation, with translocation of thrombin; the RCL is n
body of the serpin (3). The lower panel depicts the reaction of thrombin (yello
of HV3 (blue circular extension) was substituted for HCII 1-75. For this fusion pr
complex in which exosite 1 and HV3 interact without engagement of the RCL
complex forms directly (2b). Suboptimally aligned complexes from (2a) can pr
more likely with HV3API M358R than with HAPI M358R or heparin-activa
thrombin, diagrams are not to scale.ability to form a serpin-enzyme complex with thrombin
suggested that the higher affinity HV3 motif might re-
cruit α-thrombin to HV3-API proteins more effectively
than to HCII 1-75-API proteins, but orient them in a
less favourable way for attack by the thrombin active site
on the RCL. Noting that the exosite 1-binding motif in
hirudin is found on the C-terminus of the protein, we
switched the fusion point of HV3 54-66 from the N-
terminus of API M358R to the C-terminus of the serpin.
While functional, the resulting fusion protein, with or
without a spacer peptide, inhibited thrombin at rates 11-
to 14-fold less than those achieved by HV3API M358R.
C-terminal extensions are known within the serpin fam-
ily in spite of the proximity of this region to the RCL,
most notably in alpha-2-antiplasmin [1], and a C-
terminal hexahistidine extension conferred enhanced
thrombin inhibitory activity on HCII in the presence of
heparin [43]. In spite of these precedents, positioning
the exosite 1-binding motif of hirudin in this location
did not lead to enhanced function of API M358R. Thisd engineered serpins. The upper panel depicts the reaction of thrombin
e). (1) Thrombin (IIa, with pie-shaped active site canyon opening and
PI-M358R, both containing HCII 1-75 (1-75, blue teardrop-shaped extension)
oval). Interactions between HCII 1-75 and exosite 1 and the serpin RCL
x formation (2). Aligned encounter complex formation leads to final
o longer visible due to its conversion into a β-strand inserted into the
w) with HV3API M358R (blue), in which the C-terminal triskaidecapeptide
otein, initial complexes form which comprise either a sub-optimally aligned
with thrombin’s active site (2a), or the appropriately aligned encounter
oceed to optimal alignment (2b) but misalignment is predicted to be
ted HCII. Apart from the greater size of the serpins with respect to
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reasons; the HV3 motif may either have been too close
to the RCL or inappropriately angled to permit simul-
taneous productive engagement of both exosite 1 and
the active site of thrombin. Variant forms of API M358R
with attached HV3 triskaidecapeptides, in either location,
could bind thrombin via exosite-1; indeed, we demon-
strated this property of HV3API M358R using FPR-
ck-thrombin in this report. It is possible that any of the
HV3-API fusion proteins could bind thrombin exosite 1
and interfere with the subsequent attack of another HV3-
API fusion protein on the RCL. Similarly, cleavage of
the RCL in API-HV3 or API-G6-HV3 by thrombin would
liberate a small polypeptide chain commencing with P1′
and terminating with the C-terminus of the fusion pro-
teins, including the HV3 triskaidecapeptide. Competition
of these small polypeptides for exosite-1 might then have
some inhibitory effects, although it should be noted that
we previously found that a 1000-fold molar excess of HCII
1-75 peptide only reduced the rate of thrombin inhibition
by glycosaminoglycan-catalyzed HCII by approximately
4-fold [36].
The similarity between the acidic extension of HCII and
the C-terminal motif in hirudin has long been known
[32,48]. When an encounter complex structure between
thrombin S195A and HCII was solved [31], it became pos-
sible to compare the interactions between the partially re-
solved HCII extension and thrombin exosite 1 and the
corresponding, fully resolved interactions in hirudin vari-
ants 1 and 2 [49,50]. In spite of the enrichment in acidic
residues in both motifs, it was hydrophobic residues, in
helical conformation in HCII, and in a non-helical con-
formation in hirudin, that formed the closest contacts with
the hydrophobic face of exosite 1[31]. The residues in hiru-
din (HV3 numbering) include F56, I59, P60, and Y64, and
in HCII analogous residues L61, L63, I66, F67, and I74
[31]. In spite of our efforts to position HV3 54-66 in an
orientation in HV3API M358R as close as possible to the
corresponding exosite 1-binding residues in HAPI M358R,
it would appear that the conformation of the resulting fu-
sion protein was sub-optimal with respect to the two goals
of binding exosite 1 and simultaneously positioning the
RCL for efficient attack by the active site of thrombin (see
Figure 6). In native HCII, glycosaminoglycan binding is ne-
cessary, allosterically activating the serpin, to expel its RCL
from a partially inserted position in β-sheet A and stretch
it to an extent sufficient both to bind thrombin’s active site
and to permit acidic extension-exosite 1 interaction [31].
In HCII-API M358R fusion proteins, some aspects of this
optimal structure were recreated on a serpin scaffold
of similar size and conformation to glycosaminoglycan-
activated HCII. Our results in this study suggest that fur-
ther enhancements to the thrombin inhibitory capacity of
API M358R and related variants should be built on thisscaffold. For instance, one or both acidic repeats (including
related hydrophobic areas of HCII) could be replaced with
the corresponding motif from HV3, in the context of the
full HCII 1-75 extension. At least in the context of API
M358R fusion proteins [28] or isolated HCII extensions
[36], we have shown that the full extension is required for
maximal interaction with thrombin. In this regard it has
also been noted that the triple mutation D72N/Y73F/D75
confers a 4-to 6-fold increased rated of thrombin inhibition
on recombinant HCII in either the absence or presence of
glycosaminoglycans [35], and this alteration could also
form part of future API engineering efforts to increase the
potency of API as a potential antithrombotic agent.
Conclusions
In this study we have demonstrated that enhancements in
the rate of thrombin inhibition by API M358R and related
variants can be achieved by fusing a thrombin exosite 1-
binding motif on the N-terminus of the recombinant
serpin. This approach increased the rate of inhibition of α-
thrombin inhibition both for HV3API M358R, and also for
HV3API RCL5, in which six RCL residues in addition to
M358R were mutated to the corresponding residues in an-
tithrombin. Full enhancement was dependent on the integ-
rity of exosite 1 in thrombin. Although the approach was
successful in increasing the rate of thrombin inhibition, fu-
sion proteins containing the acidic extension of HCII, such
as HAPI M358R and HAPI RCL5, were faster thrombin in-
hibitors. Both in isolated and fused form, HV3 54-66 bound
thrombin exosite 1 more tightly than HCII 1-75; however,
this tight binding did not lead to enhanced rates of throm-
bin inhibition, suggesting that it may have locked the re-
combinant serpins into exosite 1-bound states that were
not optimal for subsequent serpin-enzyme complex forma-
tion. Future protein engineering of thrombin inhibitors
based on API M358R could more productively include the
high affinity of the hirudin C-terminal region if the analo-
gous residues were presented in the context of a mutated
HCII 1-75 fusion moiety.
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